Go online to PeerView.com/BBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Targeted therapies have had a beneficial role in the advanced gastric or GEJ cancer setting, and several novel strategies of combining targeted therapy with immunotherapy are evolving the treatment landscape. While medicine continues to scientifically advance, the holistic care of patients with gastric/GEJ cancers is becoming more complex, and factors such as symptom management, psychological support, and nutritional considerations, in addition to effective treatment selection, need to be considered to offer the best clinical and quality of life outcomes to patients. This three-part educational activity offers learners an exclusive look at how science and care merge in the clinic to enhance the multidisciplinary, multidirectional management of patients with gastric/GEJ cancers. Upon completion of this activity, participants will be able to: Summarize clinical evidence on established targeted therapies, such as antiangiogenic agents, and emerging combination strategies, such as with checkpoint inhibitors, for advanced gastric or gastroesophageal junction (GEJ) cancers, Select appropriate second-line targeted therapies based on treatment history, patient preference, performance status, and biomarker status for patients with advanced gastric/GEJ cancers who have progressed following first-line chemotherapy, Develop a holistic treatment plan that addresses nutrition/diet concerns, emotional distress, treatment-related adverse events, and risk of disease progression, among other issues, with a multidisciplinary and interprofessional team of clinicians who care for patients with advanced gastric/GEJ cancers.
View all episodes
